Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Follow-Up Questions
Who is the CEO of Alpha Cognition Inc?
Mr. Michael Mcfadden is the Chief Executive Officer of Alpha Cognition Inc, joining the firm since 2021.
What is the price performance of ACOG stock?
The current price of ACOG is $6.8, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Alpha Cognition Inc?
Alpha Cognition Inc belongs to Biotechnology industry and the sector is Health Care
What is Alpha Cognition Inc market cap?
Alpha Cognition Inc's current market cap is $109.8M
Is Alpha Cognition Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Alpha Cognition Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
